SRR1472394
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.471
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.385
- IL6_JAK_STAT3_SIGNALING+0.378
- COAGULATION+0.375
- HYPOXIA+0.375
- INFLAMMATORY_RESPONSE+0.374
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.352
- COMPLEMENT+0.281
- MYOGENESIS+0.280
- APOPTOSIS+0.265
Top 10 suppressed
- E2F_TARGETS-0.411
- MYC_TARGETS_V1-0.398
- G2M_CHECKPOINT-0.387
- MYC_TARGETS_V2-0.377
- DNA_REPAIR-0.368
- PROTEIN_SECRETION-0.291
- OXIDATIVE_PHOSPHORYLATION-0.241
- WNT_BETA_CATENIN_SIGNALING-0.239
- MITOTIC_SPINDLE-0.158
- UNFOLDED_PROTEIN_RESPONSE-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PJPGVD62 | Ependymoma NOS | — | 0.915 |
| 2 | SRR1355150 | GTEX | — | 0.910 |
| 3 | SRR1478946 | GTEX | — | 0.907 |
| 4 | SRR1489177 | GTEX | — | 0.900 |
| 5 | BS_PZVHMSYN | Diffuse intrinsic pontine glioma | — | 0.896 |
| 6 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.894 |
| 7 | ERR2598313 | fetal | fetal | 0.893 |
| 8 | BS_T55Y4Z0Y | low-grade glioma | — | 0.892 |
| 9 | SRR1388979 | GTEX | — | 0.891 |
| 10 | BS_3H71BH6Q | Ganglioglioma | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.471 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.385 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.378 | Inavolisib | — uncovered |
| COAGULATION | 0.375 | Binimetinib | — uncovered |
| HYPOXIA | 0.375 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.374 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.352 | Inavolisib | — uncovered |
| COMPLEMENT | 0.281 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.265 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.237 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.228 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.224 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.223 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.217 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.214 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.208 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.194 | Idelalisib | — uncovered |